These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24685546)

  • 61. Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines.
    Uria-Nickelsen M; Neckermann G; Sriram S; Andrews B; Manchester JI; Carcanague D; Stokes S; Hull KG
    Int J Antimicrob Agents; 2013 Apr; 41(4):363-71. PubMed ID: 23305654
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Probing linker design in citric acid-ciprofloxacin conjugates.
    Milner SJ; Snelling AM; Kerr KG; Abd-El-Aziz A; Thomas GH; Hubbard RE; Routledge A; Duhme-Klair AK
    Bioorg Med Chem; 2014 Aug; 22(16):4499-505. PubMed ID: 24794750
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Linker-switch approach towards new ATP binding site inhibitors of DNA gyrase B.
    Jukič M; Ilaš J; Brvar M; Kikelj D; Cesar J; Anderluh M
    Eur J Med Chem; 2017 Jan; 125():500-514. PubMed ID: 27689732
    [TBL] [Abstract][Full Text] [Related]  

  • 64. 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms.
    Ellsworth EL; Tran TP; Showalter HD; Sanchez JP; Watson BM; Stier MA; Domagala JM; Gracheck SJ; Joannides ET; Shapiro MA; Dunham SA; Hanna DL; Huband MD; Gage JW; Bronstein JC; Liu JY; Nguyen DQ; Singh R
    J Med Chem; 2006 Nov; 49(22):6435-8. PubMed ID: 17064062
    [TBL] [Abstract][Full Text] [Related]  

  • 65.
    Roney M; Issahaku AR; Forid MS; Huq AKMM; Soliman MES; Mohd Aluwi MFF; Tajuddin SN
    J Biomol Struct Dyn; 2023; 41(24):14904-14913. PubMed ID: 36995164
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
    McGarry DH; Cooper IR; Walker R; Warrilow CE; Pichowicz M; Ratcliffe AJ; Salisbury AM; Savage VJ; Moyo E; Maclean J; Smith A; Charrier C; Stokes NR; Lindsay DM; Kerr WJ
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2998-3003. PubMed ID: 30122228
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Biological profiling of novel tricyclic inhibitors of bacterial DNA gyrase and topoisomerase IV.
    Savage VJ; Charrier C; Salisbury AM; Moyo E; Forward H; Chaffer-Malam N; Metzger R; Huxley A; Kirk R; Uosis-Martin M; Noonan G; Mohmed S; Best SA; Ratcliffe AJ; Stokes NR
    J Antimicrob Chemother; 2016 Jul; 71(7):1905-13. PubMed ID: 27032669
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
    Bobesh KA; Renuka J; Jeankumar VU; Shruti SK; Sridevi JP; Yogeeswari P; Sriram D
    Eur J Med Chem; 2014 Oct; 85():593-604. PubMed ID: 25127151
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Piperazine-azole-fluoroquinolone hybrids: Conventional and microwave irradiated synthesis, biological activity screening and molecular docking studies.
    Mermer A; Faiz O; Demirbas A; Demirbas N; Alagumuthu M; Arumugam S
    Bioorg Chem; 2019 Apr; 85():308-318. PubMed ID: 30654222
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
    Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
    J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Structure activity relationship of N-1 substituted 1,5-naphthyrid-2-one analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-9).
    Singh SB; Tan CM; Kaelin D; Meinke PT; Miesel L; Olsen DB; Fukuda H; Kishii R; Takei M; Ohata K; Takeuchi T; Shibue T; Takano H; Nishimura A; Fukuda Y
    Bioorg Med Chem Lett; 2022 Nov; 75():128808. PubMed ID: 35609741
    [TBL] [Abstract][Full Text] [Related]  

  • 72. NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.
    Dougherty TJ; Nayar A; Newman JV; Hopkins S; Stone GG; Johnstone M; Shapiro AB; Cronin M; Reck F; Ehmann DE
    Antimicrob Agents Chemother; 2014 May; 58(5):2657-64. PubMed ID: 24566174
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs.
    Mann CA; Carvajal Moreno JJ; Lu Y; Dellos-Nolan S; Wozniak DJ; Yalowich JC; Mitton-Fry MJ
    Antimicrob Agents Chemother; 2023 Oct; 67(10):e0048223. PubMed ID: 37724886
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents.
    Oblak M; Kotnik M; Solmajer T
    Curr Med Chem; 2007; 14(19):2033-47. PubMed ID: 17691945
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Antibacterial action of quinolones: from target to network.
    Cheng G; Hao H; Dai M; Liu Z; Yuan Z
    Eur J Med Chem; 2013 Aug; 66():555-62. PubMed ID: 23528390
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Recent advances in DNA gyrase-targeted antimicrobial agents.
    Dighe SN; Collet TA
    Eur J Med Chem; 2020 Aug; 199():112326. PubMed ID: 32460040
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus.
    Janupally R; Jeankumar VU; Bobesh KA; Soni V; Devi PB; Pulla VK; Suryadevara P; Chennubhotla KS; Kulkarni P; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2014 Nov; 22(21):5970-87. PubMed ID: 25288496
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Synthesis, characterization, theoretical, anti-bacterial and molecular docking studies of quinoline based chalcones as a DNA gyrase inhibitor.
    Abdullah MI; Mahmood A; Madni M; Masood S; Kashif M
    Bioorg Chem; 2014 Jun; 54():31-7. PubMed ID: 24747187
    [TBL] [Abstract][Full Text] [Related]  

  • 79. De novo design of novel DNA-gyrase inhibitors based on 2D molecular fingerprints.
    Huang Z; Lin K; You Q
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4166-71. PubMed ID: 23743285
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prospects for developing new antibacterials targeting bacterial type IIA topoisomerases.
    Tomašić T; Mašič LP
    Curr Top Med Chem; 2014; 14(1):130-51. PubMed ID: 24236722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.